Related Experiment Video
Updated: May 29, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Growth in chronic kidney disease
Halima S Janjua1, John D Mahan
1Division of Nephrology, Department of Pediatrics, Nationwide Children's Hospital/The Ohio State University College of Medicine, Columbus, 43205, USA.
Insights
Children with chronic kidney disease (CKD) often experience poor growth due to growth hormone (GH) resistance. Recombinant GH (rGH) therapy can improve growth velocity in these children.
Area of Science:
- Pediatric Nephrology
- Endocrinology
- Growth Disorders
Background:
- Poor growth is a common and serious complication of chronic kidney disease (CKD) in children, impacting psychosocial development and adult health.
- Growth failure in CKD has multifactorial causes, including disruptions in the growth hormone (GH) and insulin-like growth factor-1 (IGF-1) axis.
- CKD is characterized by GH resistance, not GH deficiency, with several underlying mechanisms contributing to this resistance.
Purpose of the Study:
- To review the pathogenesis of growth failure in children with CKD.
- To discuss the effects of growth failure on children's development.
- To explore management strategies for growth failure in pediatric CKD patients.
Main Methods:
- Review of existing literature on growth failure in pediatric CKD.
- Analysis of the role of GH/IGF-1 axis dysfunction.
- Evaluation of recombinant GH (rGH) therapy efficacy and safety.
Main Results:
- Disordered GH and IGF-1 axis function are key contributors to poor growth in pediatric CKD.
- Recombinant GH (rGH) therapy is an effective and safe option to accelerate growth velocity in children with CKD.
- Despite proven benefits, rGH therapy is underutilized in this population due to practitioner and family hesitancy.
Conclusions:
- Growth failure in children with CKD is a complex issue requiring targeted management strategies.
- Understanding GH resistance is crucial for addressing poor growth in pediatric CKD.
- Increased awareness and acceptance of rGH therapy could improve growth outcomes for children with CKD.
Abstract:
Poor growth is a common sequela of CKD in childhood. It not only affects the psychosocial development of a child but also has significant effects even in the adult life. The multifactorial etiology and severe consequences of growth failure in CKD warrant evaluation of all the modifiable and nonmodifiable causes. Treatment strategies must be directed toward the specific factors for each child with CKD. Among the various metabolic, nutritional, and hormonal disturbances complicating CKD, disordered growth hormone (GH) and insulin-like growth factor-1 axis are important contributors toward poor growth in children with CKD. CKD is recognized as a state of GH resistance rather than GH deficiency, with multiple mechanisms contributing to this GH resistance. Recombinant GH (rGH) therapy can be used in this population to accelerate growth velocity. Although its use has been shown to be effective and safe in children with CKD, there continues to be some uncertainty and reluctance among practitioners and families regarding its usage, thereby resulting in a surprisingly low use in children with CKD. This review focuses on the pathogenesis of growth failure, its effect, and management strategies in children with CKD.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury III: Clinical Manifestations
Chronic Kidney Disease IV: Nursing Management
Nephrons
